Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Documentation

  • Home >
  • Investors & media >
  • Documentation
10 May 2017
General meetings

Proxy card 2016 General Meeting Open in new window

10 May 2017
General meetings

Nominees and renewals to the Board of Directors Open in new window

10 May 2017
General meetings

Number of voting rights and outstanding shares Open in new window

10 May 2017
General meetings

Report of the Board of Directors on the grant of performance shares (AGA) Open in new window

10 May 2017
General meetings

Notice of meeting of the General Meeting on May 31, 2017 Open in new window

10 May 2017
General meetings

Supplementary report of the Board on the conversion of preferred shares on July 12, 2016 Open in new window

10 May 2017
General meetings

Supplementary report of the Board on the issuance of ordinary shares on August 10, 2016 Open in new window

28 April 2017
Financial statements and reports

2016 Registration Document Open in new window

  • View previous 9 articles
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page